Next Article in Journal
Glycaemic Imbalances in Seizures and Epilepsy of Paediatric Age: A Literature Review
Previous Article in Journal
Endotoxemia in Acute Heart Failure and Cardiogenic Shock: Evidence, Mechanisms and Therapeutic Options
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828

1
Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan
2
Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka 530-0011, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(7), 2578; https://doi.org/10.3390/jcm12072578
Submission received: 16 March 2023 / Accepted: 20 March 2023 / Published: 29 March 2023
(This article belongs to the Section Cardiology)

Error in Figure

In the original publication [1], there was a mistake in Figure 3 as published. Some prescription numbers and percentages in ACEi, ARB and MRA were wrong. The corrected Figure 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Kohsaka, S.; Okami, S.; Morita, N.; Yajima, T. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828. [Google Scholar] [CrossRef] [PubMed]
Figure 3. RAASi treatment according to dosage category (high, medium, or low) at the index date. Percentages were calculated using the total number of prescriptions. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; RAASi, renin–angiotensin–aldosterone system inhibitor.
Figure 3. RAASi treatment according to dosage category (high, medium, or low) at the index date. Percentages were calculated using the total number of prescriptions. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; RAASi, renin–angiotensin–aldosterone system inhibitor.
Jcm 12 02578 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kohsaka, S.; Okami, S.; Morita, N.; Yajima, T. Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828. J. Clin. Med. 2023, 12, 2578. https://doi.org/10.3390/jcm12072578

AMA Style

Kohsaka S, Okami S, Morita N, Yajima T. Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828. Journal of Clinical Medicine. 2023; 12(7):2578. https://doi.org/10.3390/jcm12072578

Chicago/Turabian Style

Kohsaka, Shun, Suguru Okami, Naru Morita, and Toshitaka Yajima. 2023. "Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828" Journal of Clinical Medicine 12, no. 7: 2578. https://doi.org/10.3390/jcm12072578

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop